These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody. Melo-Carrillo A; Noseda R; Nir RR; Schain AJ; Stratton J; Strassman AM; Burstein R J Neurosci; 2017 Jul; 37(30):7149-7163. PubMed ID: 28642283 [TBL] [Abstract][Full Text] [Related]
3. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD. Strassman AM; Melo-Carrillo A; Houle TT; Adams A; Brin MF; Burstein R Cephalalgia; 2022 Aug; 42(9):933-943. PubMed ID: 35332801 [TBL] [Abstract][Full Text] [Related]
4. Novel insight into atogepant mechanisms of action in migraine prevention. Melo-Carrillo A; Strassman AM; Broide R; Adams A; Dabruzzo B; Brin M; Burstein R Brain; 2024 Aug; 147(8):2884-2896. PubMed ID: 38411458 [TBL] [Abstract][Full Text] [Related]
5. Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats. Melo-Carrillo A; Strassman AM; Malcolm KJ; Adams AM; Dabruzzo B; Briode RS; Brin MF; Burstein R Cephalalgia; 2024 Sep; 44(9):3331024241278919. PubMed ID: 39252510 [TBL] [Abstract][Full Text] [Related]
6. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Melo-Carrillo A; Strassman AM; Schain AJ; Noseda R; Ashina S; Adams A; Brin MF; Burstein R Cephalalgia; 2019 Oct; 39(11):1358-1365. PubMed ID: 31475573 [TBL] [Abstract][Full Text] [Related]
7. Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Melo-Carrillo A; Strassman AM; Schain AJ; Adams AM; Brin MF; Burstein R Cephalalgia; 2021 Jan; 41(1):17-32. PubMed ID: 33200944 [TBL] [Abstract][Full Text] [Related]
8. CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura. Schain AJ; Melo-Carrillo A; Stratton J; Strassman AM; Burstein R J Neurosci; 2019 Jul; 39(30):6001-6011. PubMed ID: 31127003 [TBL] [Abstract][Full Text] [Related]
9. Activation of Peripheral and Central Trigeminovascular Neurons by Seizure: Implications for Ictal and Postictal Headache. Melo-Carrillo A; Schain AJ; Strassman AM; Burstein R J Neurosci; 2020 Jul; 40(27):5314-5326. PubMed ID: 32527981 [TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Levy D; Burstein R; Strassman AM Ann Neurol; 2005 Nov; 58(5):698-705. PubMed ID: 16240341 [TBL] [Abstract][Full Text] [Related]
11. Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Noseda R; Schain AJ; Melo-Carrillo A; Tien J; Stratton J; Mai F; Strassman AM; Burstein R Cephalalgia; 2020 Mar; 40(3):229-240. PubMed ID: 31856583 [TBL] [Abstract][Full Text] [Related]
12. Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset. Zhao J; Levy D J Neurosci; 2018 May; 38(22):5053-5066. PubMed ID: 29703787 [TBL] [Abstract][Full Text] [Related]
13. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. Eftekhari S; Warfvinge K; Blixt FW; Edvinsson L J Pain; 2013 Nov; 14(11):1289-303. PubMed ID: 23958278 [TBL] [Abstract][Full Text] [Related]
14. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Ma QP; Hill R; Sirinathsinghji D Eur J Neurosci; 2001 Jun; 13(11):2099-104. PubMed ID: 11422450 [TBL] [Abstract][Full Text] [Related]
15. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. Edvinsson JCA; Warfvinge K; Krause DN; Blixt FW; Sheykhzade M; Edvinsson L; Haanes KA J Headache Pain; 2019 Nov; 20(1):105. PubMed ID: 31718551 [TBL] [Abstract][Full Text] [Related]
16. Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier. Melo-Carrillo A; Schain AJ; Stratton J; Strassman AM; Burstein R Pain; 2020 May; 161(5):1037-1043. PubMed ID: 31895266 [TBL] [Abstract][Full Text] [Related]
17. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. Haanes KA; Edvinsson L CNS Drugs; 2019 Jun; 33(6):525-537. PubMed ID: 30989485 [TBL] [Abstract][Full Text] [Related]
18. The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow. Dux M; Vogler B; Kuhn A; Mackenzie KD; Stratton J; Messlinger K Cells; 2022 May; 11(11):. PubMed ID: 35681463 [TBL] [Abstract][Full Text] [Related]
19. Fremanezumab for the preventive treatment of migraine in adults. Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963 [No Abstract] [Full Text] [Related]
20. Local application of morphine suppresses glutamate-evoked activities of C and Adelta afferent fibers in rat hairy skin. Tian YL; Guo Y; Cao DY; Zhang Q; Wang HS; Zhao Y Brain Res; 2005 Oct; 1059(1):28-34. PubMed ID: 16168967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]